<?xml version="1.0" encoding="UTF-8"?>
<rootTag>
<Award>
<AwardTitle>SBIR Phase I:  A knowledge base and drug repurposing platform for COVID-19</AwardTitle>
<AGENCY>NSF</AGENCY>
<AwardEffectiveDate>08/01/2020</AwardEffectiveDate>
<AwardExpirationDate>07/31/2022</AwardExpirationDate>
<AwardTotalIntnAmount>255993.00</AwardTotalIntnAmount>
<AwardAmount>255993</AwardAmount>
<AwardInstrument>
<Value>Standard Grant</Value>
</AwardInstrument>
<Organization>
<Code>07070000</Code>
<Directorate>
<Abbreviation>ENG</Abbreviation>
<LongName>Directorate For Engineering</LongName>
</Directorate>
<Division>
<Abbreviation>IIP</Abbreviation>
<LongName>Div Of Industrial Innovation &amp; Partnersh</LongName>
</Division>
</Organization>
<ProgramOfficer>
<SignBlockName>Erik Pierstorff</SignBlockName>
<PO_EMAI>epiersto@nsf.gov</PO_EMAI>
<PO_PHON>7032922165</PO_PHON>
</ProgramOfficer>
<AbstractNarration>The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project is to create a software platform to facilitate the identification of existing drugs that can be re-purposed for other diseases, such as COVID-19.  First, identifying FDA-approved drugs that could help COVID-19 patients is expected to save lives. Furthermore, this can prevent the economic consequences of extended or repeated mass quarantine episodes. Finally, the availability of a drug discovery platform for flu-like viruses that includes data from SARS-CoV-2 and other related viruses will add to the national cyberinfrastructure and will allow a better response at the next occurrence of a novel virus.&lt;br/&gt; &lt;br/&gt;The proposed project will develop a prototype platform to include: i) state-of-the-art data analysis methods, ii) a comprehensive knowledge base, and iii) an approach complementary to most other avenues currently pursued in the fight against COVID-19. The approach will focus on leveraging transcriptomics and other omics data focusing on the hostâ€™s immune response.  This system will enable efficient research into issues such as the acute reaction of the immune systems, enabling approaches to mitigate and/or avoid a cytokine storm.  This provides important information complementary to development of antiviral medications or vaccines, important for a future pandemic regardless of the virus strain.&lt;br/&gt;&lt;br/&gt;This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.</AbstractNarration>
<MinAmdLetterDate>08/04/2020</MinAmdLetterDate>
<MaxAmdLetterDate>07/20/2021</MaxAmdLetterDate>
<ARRAAmount/>
<TRAN_TYPE>Grant</TRAN_TYPE>
<CFDA_NUM>47.041</CFDA_NUM>
<NSF_PAR_USE_FLAG>1</NSF_PAR_USE_FLAG>
<FUND_AGCY_CODE>4900</FUND_AGCY_CODE>
<AWDG_AGCY_CODE>4900</AWDG_AGCY_CODE>
<AwardID>2029572</AwardID>
<Investigator>
<FirstName>Cordelia</FirstName>
<LastName>Ziraldo</LastName>
<PI_MID_INIT>R</PI_MID_INIT>
<PI_SUFX_NAME/>
<PI_FULL_NAME>Cordelia R Ziraldo</PI_FULL_NAME>
<EmailAddress>cordelia@advaitabio.com</EmailAddress>
<PI_PHON>7349220110</PI_PHON>
<NSF_ID>000739692</NSF_ID>
<StartDate>08/04/2020</StartDate>
<EndDate>07/20/2021</EndDate>
<RoleCode>Former Principal Investigator</RoleCode>
</Investigator>
<Investigator>
<FirstName>Aaron</FirstName>
<LastName>denDekker</LastName>
<PI_MID_INIT>D</PI_MID_INIT>
<PI_SUFX_NAME/>
<PI_FULL_NAME>Aaron D denDekker</PI_FULL_NAME>
<EmailAddress>aaron@advaitabio.com</EmailAddress>
<PI_PHON>7349220110</PI_PHON>
<NSF_ID>000860325</NSF_ID>
<StartDate>07/20/2021</StartDate>
<EndDate/>
<RoleCode>Principal Investigator</RoleCode>
</Investigator>
<Institution>
<Name>Advaita Corporation</Name>
<CityName>Ann Arbor</CityName>
<ZipCode>481052552</ZipCode>
<PhoneNumber>7349220110</PhoneNumber>
<StreetAddress>3250 Plymouth Rd. #303</StreetAddress>
<StreetAddress2/>
<CountryName>United States</CountryName>
<StateName>Michigan</StateName>
<StateCode>MI</StateCode>
<CONGRESSDISTRICT>12</CONGRESSDISTRICT>
<CONGRESS_DISTRICT_ORG>MI12</CONGRESS_DISTRICT_ORG>
<ORG_DUNS_NUM>198047529</ORG_DUNS_NUM>
<ORG_LGL_BUS_NAME>ADVAITA CORPORATION</ORG_LGL_BUS_NAME>
<ORG_PRNT_DUNS_NUM/>
</Institution>
<Performance_Institution>
<Name><![CDATA[Advaita Corporation]]></Name>
<CityName>Ann Arbor</CityName>
<StateCode>MI</StateCode>
<ZipCode>481052552</ZipCode>
<StreetAddress><![CDATA[3250 Plymouth Rd. #303]]></StreetAddress>
<CountryCode>US</CountryCode>
<CountryName>United States</CountryName>
<StateName>Michigan</StateName>
<CountryFlag>1</CountryFlag>
<CONGRESSDISTRICT>12</CONGRESSDISTRICT>
<CONGRESS_DISTRICT_PERF>MI12</CONGRESS_DISTRICT_PERF>
</Performance_Institution>
<ProgramElement>
<Code>5371</Code>
<Text>SBIR Phase I</Text>
</ProgramElement>
<ProgramReference>
<Code>096Z</Code>
<Text>COVID-19 Research</Text>
</ProgramReference>
<ProgramReference>
<Code>1718</Code>
<Text>BIOINFORMATICS</Text>
</ProgramReference>
<ProgramReference>
<Code>8038</Code>
<Text>Biotechnology</Text>
</ProgramReference>
<Appropriation>
<Code>0120</Code>
<Name>NSF RESEARCH &amp; RELATED ACTIVIT</Name>
<APP_SYMB_ID>040100</APP_SYMB_ID>
</Appropriation>
<FUND_OBLG>2020~255993</FUND_OBLG>
</Award>
</rootTag>
